Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Royalty Pharma plc (NASDAQ: RPRX)
RPRX Stock Predictions and Ratings
WSX Rating:
BUY
WSX Forecast (1yr):
7%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
6.60%
RPRX Stock Analysis
RPRX
PE Ratio:
28.8
RPRX
PEG Ratio:
4.3
RPRX
Forward EPS Growth (12 month):
6.70%
RPRX
PS Ratio:
9.7
RPRX
PSG Ratio:
1.5
RPRX
Forward Revenue Growth (12 month):
6.40%
RPRX Articles
No data was found